Outstanding Research Achievement Award
Antonio Lugini
AO San Giovanni Addolorata Hospital, Italy
Antonio Lugini is an oncology researcher affiliated with AO San Giovanni Addolorata Hospital whose scholarly activities focus on clinical oncology, translational medicine, biomarker discovery, and precision cancer research. His publication profile demonstrates sustained engagement with multidisciplinary approaches that integrate clinical evidence, biomedical data, and patient-centered treatment strategies. With an h-index of 10 and 328 citations, his research has contributed to ongoing scientific discussions concerning lung cancer management and innovative clinical research infrastructures.[1]
Abstract
This article recognizes Antonio Lugini for contributions to oncology research, particularly in precision medicine and translational cancer studies. His work supports the integration of clinical data, biological markers, and evidence-based therapeutic approaches aimed at improving outcomes for patients with lung cancer. Recent publications highlight innovative data-driven frameworks and investigations of prognostic indicators relevant to modern oncology practice.[2]
Keywords
Oncology, Precision Medicine, Lung Cancer, Translational Research, Clinical Biomarkers, Cancer Informatics, Immunotherapy, Healthcare Analytics.
Introduction
Contemporary oncology increasingly depends on collaborative research that combines clinical observations with advanced analytical methodologies. Antonio Lugini’s research activities align with this trend by exploring how biomedical evidence can support diagnosis, treatment planning, and translational applications in cancer care.[1]
Research Profile
The researcher has established a recognized profile in oncology with measurable scholarly impact reflected through citation performance and a sustained publication record. His work frequently addresses lung cancer, patient stratification, treatment evaluation, and evidence generation for clinical decision-making.[1]
Research Contributions
Key contributions include participation in the APOLLO11 initiative, a bio-data-driven framework supporting clinical and translational lung cancer research, and investigations into the prognostic value of the neutrophil-lymphocyte ratio among patients receiving Durvalumab treatment. These studies contribute to precision oncology and clinical outcome assessment.[2][3]
Publications
- APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.
- Retrospective evaluation of the neutrophil-lymphocyte ratio in unresectable stage III NSCLC treated with Durvalumab.
Research Impact
With 328 citations and an h-index of 10, Antonio Lugini’s work demonstrates scholarly visibility and relevance within oncology research communities. His studies contribute evidence that supports precision treatment pathways and data-informed clinical investigations.[1]
Award Suitability
Antonio Lugini is a suitable recipient for the Outstanding Research Achievement Award due to his documented publication record, citation impact, and contributions to clinically relevant oncology research. His interdisciplinary work advances translational science while fostering evidence-based healthcare innovation.[1]
Conclusion
The academic profile of Antonio Lugini reflects meaningful engagement in oncology and translational medicine. Through contributions to lung cancer research, biomarker evaluation, and clinical data integration, he has demonstrated research excellence worthy of recognition within an international scholarly framework.
External Links
References
- Elsevier. (n.d.). Scopus author details: Antonio Lugini, Author ID 6505973456. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=6505973456
- Npj Precision Oncology. (2026). APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer. https://www.nature.com/articles/s41698-026-01295-3
- Cancer Treatment and Research Communications. (2026). Retrospective evaluation of the neutrophil-lymphocyte ratio in stage III NSCLC treated with Durvalumab. https://pubmed.ncbi.nlm.nih.gov/41707549/